{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Ureter+Cancer+AJCC+v7",
    "query": {
      "condition": "Stage II Ureter Cancer AJCC v7"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:10:04.907Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07087860",
      "title": "Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma",
        "Refractory Bladder Urothelial Carcinoma",
        "Refractory Renal Pelvis and Ureter Urothelial Carcinoma",
        "Stage IV Bladder Cancer AJCC v7",
        "Stage IV Renal Pelvis and Ureter Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Central Venous Cannula Insertion",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plasmapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Antibody-Drug Conjugate Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-08-01",
      "completion_date": "2028-08-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-05-22T03:10:04.907Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07087860"
    },
    {
      "nct_id": "NCT05987241",
      "title": "Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma",
        "Muscle Invasive Renal Pelvis Urothelial Carcinoma",
        "Muscle Invasive Ureter Urothelial Carcinoma",
        "Muscle Invasive Urethral Urothelial Carcinoma",
        "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage IV Bladder Urothelial Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "cfDNA or ctDNA Measurement",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Relatlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 992,
      "start_date": "2024-02-02",
      "completion_date": "2030-09-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-05-22T03:10:04.907Z",
      "location_count": 487,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 367 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05987241"
    },
    {
      "nct_id": "NCT02812420",
      "title": "Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hydronephrosis",
        "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant",
        "Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant",
        "Renal Pelvis Urothelial Carcinoma",
        "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage II Renal Pelvis Cancer AJCC v7",
        "Stage II Ureter Cancer AJCC v7",
        "Stage II Urethral Cancer AJCC v7",
        "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage III Renal Pelvis Cancer AJCC v7",
        "Stage III Ureter Cancer AJCC v7",
        "Stage III Urethral Cancer AJCC v7",
        "Stage IV Renal Pelvis Cancer AJCC v7",
        "Stage IV Ureter Cancer AJCC v7",
        "Stage IV Urethral Cancer AJCC v7",
        "Ureter Urothelial Carcinoma",
        "Urethral Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2017-03-07",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-05-22T03:10:04.907Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02812420"
    },
    {
      "nct_id": "NCT03244384",
      "title": "Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Localized Renal Pelvis and Ureter Urothelial Carcinoma",
        "Locally Advanced Bladder Urothelial Carcinoma",
        "Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma",
        "Locally Advanced Ureter Urothelial Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage II Renal Pelvis and Ureter Cancer AJCC v7",
        "Stage II Ureter Cancer AJCC v7",
        "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage III Renal Pelvis and Ureter Cancer AJCC v7",
        "Stage III Ureter Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "CT Urography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 739,
      "start_date": "2017-11-03",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T03:10:04.907Z",
      "location_count": 915,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 572 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03244384"
    },
    {
      "nct_id": "NCT03617913",
      "title": "Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
        "Stage II Bladder Cancer AJCC v8",
        "Stage II Renal Pelvis Cancer AJCC v8",
        "Stage II Ureter Cancer AJCC v8",
        "Stage II Urethral Cancer AJCC v8",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Urethral Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Mitomycin",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2018-09-19",
      "completion_date": "2020-07-27",
      "has_results": true,
      "last_update_posted_date": "2023-01-06",
      "last_synced_at": "2026-05-22T03:10:04.907Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03617913"
    },
    {
      "nct_id": "NCT04398368",
      "title": "Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage 0a Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage 0a Renal Pelvis Cancer AJCC v8",
        "Stage 0a Ureter Cancer AJCC v8",
        "Stage 0is Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage 0is Renal Pelvis Cancer AJCC v8",
        "Stage 0is Ureter Cancer AJCC v8",
        "Stage I Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage I Renal Pelvis Cancer AJCC v8",
        "Stage I Ureter Cancer AJCC v8",
        "Stage II Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage II Renal Pelvis Cancer AJCC v8",
        "Stage II Ureter Cancer AJCC v8",
        "Stage III Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage IV Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2020-06-05",
      "completion_date": "2023-02-02",
      "has_results": true,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-05-22T03:10:04.907Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Rochester, Minnesota • Winston-Salem, North Carolina + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04398368"
    },
    {
      "nct_id": "NCT02178241",
      "title": "Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Ureter Carcinoma",
        "Metastatic Urethral Carcinoma",
        "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage III Ureter Cancer AJCC v7",
        "Stage III Urethral Cancer AJCC v7",
        "Stage IV Bladder Urothelial Carcinoma AJCC v7",
        "Stage IV Ureter Cancer AJCC v7",
        "Stage IV Urethral Cancer AJCC v7",
        "Ureter Urothelial Carcinoma",
        "Urethral Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Eribulin Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2014-12-11",
      "completion_date": "2019-07-11",
      "has_results": true,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-05-22T03:10:04.907Z",
      "location_count": 17,
      "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178241"
    },
    {
      "nct_id": "NCT00749892",
      "title": "Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Bladder Urothelial Carcinoma",
        "Recurrent Renal Pelvis Urothelial Carcinoma",
        "Recurrent Ureter Urothelial Carcinoma",
        "Recurrent Urethral Urothelial Carcinoma",
        "Stage 0a Bladder Cancer AJCC v8",
        "Stage 0a Renal Pelvis Cancer AJCC v8",
        "Stage 0a Ureter Cancer AJCC v8",
        "Stage 0a Urethral Cancer AJCC v8",
        "Stage 0is Bladder Cancer AJCC v8",
        "Stage 0is Renal Pelvis Cancer AJCC v8",
        "Stage 0is Ureter Cancer AJCC v8",
        "Stage 0is Urethral Cancer AJCC v8",
        "Stage II Bladder Cancer AJCC v8",
        "Stage II Renal Pelvis Cancer AJCC v8",
        "Stage II Ureter Cancer AJCC v8",
        "Stage II Urethral Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2008-06-10",
      "completion_date": "2019-11-26",
      "has_results": true,
      "last_update_posted_date": "2020-09-10",
      "last_synced_at": "2026-05-22T03:10:04.907Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00749892"
    }
  ]
}